PharmAbcine

43 articles with PharmAbcine

• PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

  5/11/2022

  PharmAbcine Inc. announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to participate at Jefferies Global Healthcare Conference over June 8-10, 2022 in New York, NY.

• PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

  4/26/2022

  PharmAbcine Inc. announced the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-activating antibody.

• PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

  4/26/2022

  PharmAbcine Inc. announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.

• PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

  4/11/2022

  PharmAbcine Inc. announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA antibody candidate at AACR (American Association for Cancer Research) 2022.

• PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022

  3/8/2022

  PharmAbcine Inc., a clinical-stage biotech company focusing on the development of antibody therapeutics, announced that the Company will present the updated data of PMC-309, one of the Company's first immuno-oncology drug candidates, at AACR 2022.

• PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

  2/25/2022

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer) patients in Australia.

• PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC

  12/27/2021

  PharmAbcine Inc. today announced it has dosed the first patient in its Phase II clinical trial evaluating the combination of olinvacimab, PharmAbcine's anti-VEGFR2.

• PharmAbcine to participate in J.P. Morgan Healthcare Conference and Biotech Showcase during "J.P. Morgan Week 2022"

  12/6/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to participate in 40th Annual J.P. Morgan Healthcare Conference over January 10-13, 2022.

• PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody

  10/19/2021

  PharmAbcine Inc. announced today that the patent for PMC-309, one of the Company's first immuno-oncology assets, has been granted by IP Australia, the Australian government agency

• PharmAbcine to Participate in BIO-Europe 2021

  9/20/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will take place from October 25 - 28, 2021.

• PharmAbcine to Participate in ACCESS CHINA Biotech Forum

  9/13/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESS CHINA Biotech Forum.

• PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer

  9/9/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), today announced it submitted a Patent Cooperation Treaty (PCT) application for the combination therapy of olinvacimab, the Company's anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 antibody, for the treatment of cancer.

• PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

  9/3/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II combination trial of olinvacimab, PharmAbcine's anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab).

• PharmAbcine to Participate in H.C. Wainright 23rd Annual Global Investment Conference

  8/23/2021

  PharmAbcine Inc. announced today that the Company will participate in H.C. Wainright 23 rd Annual Global Investment Conference taking place virtually from September 13-15, 2021 .

• PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

  8/19/2021

  PharmAbcine Inc. today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for an anti-ANG2 (Angiopoietin 2) antibody.

• PharmAbcine to Participate in Biotechgate Digital Partnering

  8/17/2021

  PharmAbcine Inc. announced today that the Company will participate in Biotechgate Digital Partnering taking place virtually from August 30 – September 3, 2021 .

• PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference

  7/26/2021

  PharmAbcine Inc. announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmology Virtual Conference on August 17, 2021 .

• PharmAbcine to Present at the BIO Digital International Convention 2021

  6/2/2021

  PharmAbcine Inc., a clinical-stage biotech company focusing on the development of antibody therapeutics, announced that the company will participate in BIO Digital International Convention.

• PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

  5/10/2021

  PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5 th . 

• PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

  4/26/2021

   PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.